ICER's Favorable Assessment Of Bluebird Bio's Gene Therapy Zynteglo May Have Important Pricing And Reimbursement Implications
ZYNTEGLO® (betibeglogene autotemcel)
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
Bluebird's $2.8M gene therapy Zynteglo gets FDA backing
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions - bluebird bio, Inc.
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
Patient group echoes bluebird bio stance over Zynteglo UK funding snub
Bluebird puts €1.57m price on gene therapy Zynteglo - PMLiVE
bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
FDA approves bluebird bio's Zynteglo for beta-thalassemia - BIO.News
FDA Approves $2.8 million Gene Tx - Zynteglo - Anton Health
FDA approves bluebird bio's Zynteglo gene therapy for beta thalassemia; shares up 7% | Seeking Alpha
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
NEW | Bluebirdbio Releases Resources For Patients On Gene Therapy Zynteglo® – TIF
Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
Potential blockbusters make a splash on market entry - Clarivate
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
FDA Approves bluebird bio's ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia - The Cooley's Anemia Foundation
Bluebird Bio Withdraws Zynteglo From Germany Over Pricing :: Pink Sheet
NICE turns down bluebird bio's gene therapy Zynteglo - PMLiVE
bluebird claims first approval for gene therapy Zynteglo in EU -
blue-ex992_54.htm
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business Wire
